The first group of participants, about 600 volunteers, received two doses of the BioNTech or Pfizer COVID-19 vaccine 90 to 180 days before the start of the study. They will receive one or two doses of the new vaccine based on Omicron, according to the statement.
The second group, which is almost as large, will include people who have received three doses of the vaccine and will then receive a dose of the BioNTech or Pfizer COVID-19 vaccine or an Omicron-based vaccine, Xinhua news agency reported. believe.
The third group will include about 200 unvaccinated people who have not previously been vaccinated against COVID-19. People in this group will receive three doses of the new vaccine based on Omicron, according to the statement.
“Maintaining vigilance against the virus requires us to identify new approaches for people to maintain a high level of protection, and we believe in developing and researching vaccines,” said Kathrin Jansen. Variant-based applications, like this one, are essential in our efforts towards this goal,” said Pfizer Senior Vice President.